Diabetes & Coronary Disease
Sort by:
13th Orange County Symposium for Cardiovascular Disease Prevention
The Gut Microbiome: Friend or Foe?
FEATURING
Rob Greenfield
- 1,185 views
- January 26, 2022
- 13
Houston Methodist DeBakey Heart and Vascular Center
Aspirin for the Primary Prevention of Cardiovascular Disease: What Changed?
FEATURING
Michael Miedema
- 3,371 views
- January 25, 2022
- 24
Piedmont Heart Institute
Cardiometabolic Therapies: GLP-1 RAs and SGLT-2i
FEATURING
Jaime Burkle
- 1,738 views
- January 25, 2022
- 18
The Texas Heart Institute
Update of Diabetes Treatment: Overview of Current Trials and ADA Practice Recommendations
FEATURING
David Aguilar
- 776 views
- November 11, 2021
- 6
Practical Ways to Achieve Targets in Diabetes Care
Role of Lipoprotein (a) in Coronary Disease: An Emerging Novel Target
FEATURING
Steven Nissen
- 4,147 views
- November 8, 2021
- 30
Houston Methodist DeBakey Heart and Vascular Center
Q&A: Four Pillars of CVD Prevention
- 19 views
- October 18, 2021
Houston Methodist DeBakey Heart and Vascular Center
Practical Tips for Managing CVD Risk Among High-Risk Diabetes
FEATURING
Michael Blaha
- 507 views
- October 18, 2021
- 5
American Heart & Vascular Institute
Heart Failure With Preserved Ejection Fraction: Is the New Paradigm Treatment Finally Here? Insights from the EMPEROR-Preserved Trial
FEATURING
Javed Butler
- 1,739 views
- September 9, 2021
- 12
American Heart & Vascular Institute
Cardiovascular Updates for Healthcare Professionals: Team Sport of Initiating SGLT2i
FEATURING
Harold Bays
- 439 views
- September 9, 2021
- 4
American Heart & Vascular Institute
Q&A: Understanding SGLT-2 Inhibitors in the CardioNephroEndo Space
- 503 views
- September 9, 2021
Complex Coronary Cases
Revascularization in Patients with SIHD, Multivessel CAD, ACS and LM Disease: PCI or CABG?
FEATURING
Jennifer S. Lawton
- 310 views
- July 14, 2021
- 2
Piedmont Heart Institute
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
FEATURING
Denise Reedus,
Barbara Conlon
- 41 views
- July 13, 2021
Emory Diabetes Education Training Academy
SGLT2-i Impact on Renal or HF Outcomes: What Is Observed in Non-Diabetic Patients?
FEATURING
Francisco Pasquel
- 264 views
- April 26, 2021
Heart Failure 2021: An Update on Therapy
Intersection of Race and Heart Failure: How to Reduce Disparities?
FEATURING
Ileana Pina
- 18 views
- March 31, 2021
ASPC 2020 Virtual Summit on CVD Prevention
Integrating Imaging & Advanced Blood Testing for CVD Prevention/Management: How Do We Know If the Patient Is in Prediabetes Phase? Why Do Lipoproteins Become Atherogenic? What Is the Role of Non-Lifestyle Genetic Markers?
FEATURING
Arthur Agatston
- 483 views
- March 24, 2021
- 3
San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
Approaches to Treating Diabetes that Reduce CV Events: How Effective Are DPP-4 Inhibitors, GLP1-Receptor Agonists and SGLT-2 Inhibitors in Reducing MACE and Preventing HF Events?
FEATURING
Jia Shen
- 337 views
- February 5, 2021
- 4